Fulcrum Therapeutics (FULC)
(Real Time Quote from BATS)
$7.14 USD
+0.01 (0.14%)
Updated Apr 26, 2024 01:04 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Fulcrum Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -97.34 | -109.87 | -80.85 | -70.82 | -82.68 |
Depreciation/Amortization & Depletion | 2.17 | 2.41 | 2.52 | 2.38 | 2.05 |
Net Change from Assets/Liabilities | -4.61 | -3.09 | -11.89 | 7.50 | 11.33 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.81 | 13.50 | 11.74 | 7.28 | 29.82 |
Net Cash From Operating Activities | -90.97 | -97.05 | -78.48 | -53.66 | -39.48 |
Property & Equipment | -0.51 | -1.96 | -1.71 | -1.34 | -0.85 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -36.18 | 14.38 | -127.96 | -55.80 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | -0.09 |
Net Cash from Investing Activities | -36.69 | 12.41 | -129.67 | -57.14 | -0.94 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 118.12 | 84.32 | 186.53 | 71.18 | 64.39 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.02 | -0.05 | -0.05 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 118.12 | 84.32 | 186.51 | 71.13 | 64.34 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -9.54 | -0.31 | -21.64 | -39.66 | 23.92 |
Cash at Beginning of Period | 36.19 | 36.50 | 58.14 | 97.81 | 73.89 |
Cash at End of Period | 26.66 | 36.19 | 36.50 | 58.14 | 97.81 |
Diluted Net EPS | -1.59 | -2.44 | -2.29 | -2.79 | -8.13 |
Fiscal Year End for Fulcrum Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -97.34 | -72.58 | -48.56 | -24.78 |
Depreciation/Amortization & Depletion | NA | 2.17 | 1.66 | 1.13 | 0.57 |
Net Change from Assets/Liabilities | NA | -4.61 | -3.58 | -2.01 | -2.79 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 8.81 | 6.69 | 4.54 | 2.89 |
Net Cash From Operating Activities | NA | -90.97 | -67.81 | -44.90 | -24.12 |
Property & Equipment | NA | -0.51 | -0.43 | -0.37 | -0.17 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -36.18 | -54.62 | -73.70 | -93.77 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -36.69 | -55.05 | -74.07 | -93.94 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 118.12 | 117.84 | 117.84 | 117.69 |
Issuance (Repayment) of Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | NA | 118.12 | 117.84 | 117.84 | 117.69 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -9.54 | -5.02 | -1.13 | -0.36 |
Cash at Beginning of Period | NA | 36.19 | 36.19 | 36.19 | 36.19 |
Cash at End of Period | NA | 26.66 | 31.17 | 35.06 | 35.83 |
Diluted Net EPS | NA | -0.41 | -0.39 | -0.38 | -0.41 |